Welcome to our dedicated page for Incyte news (Ticker: INCY), a resource for investors and traders seeking the latest updates and insights on Incyte stock.
News for Incyte Genomics Inc (Nasdaq: INCY), operating as Incyte Corporation, centers on its activities as a global biopharmaceutical company focused on Oncology and Inflammation & Autoimmunity. Company releases describe a portfolio of first‑in‑class medicines and a pipeline of proprietary therapeutics, making INCY news particularly relevant for investors and healthcare observers following cancer and immune‑related drug development.
Recent headlines highlight late-stage clinical trial results and regulatory milestones. Incyte has reported positive topline data from the Phase 3 frontMIND trial of tafasitamab (Monjuvi/Minjuvi) plus lenalidomide and R‑CHOP as first‑line therapy for diffuse large B‑cell lymphoma, meeting primary and key secondary endpoints. Other news covers European Commission and Japanese approvals of Minjuvi in combination regimens for relapsed or refractory follicular lymphoma and DLBCL, underscoring the company’s role in B‑cell lymphoma treatment.
In immuno‑oncology, Incyte Biosciences Japan G.K. has announced approval of Zynyz (retifanlimab) with platinum‑based chemotherapy as first‑line treatment for advanced squamous cell carcinoma of the anal canal, following earlier U.S. approval in a similar setting. Additional coverage describes submissions to European regulators and the broader POD1UM clinical program evaluating retifanlimab across solid tumors.
News flow also features pipeline updates for INCA033989, a first‑in‑class mutCALR‑targeted monoclonal antibody for myeloproliferative neoplasms. Incyte has disclosed Breakthrough Therapy designation from the U.S. FDA for essential thrombocythemia with Type 1 CALR mutations, along with Phase 1 data in ET and myelofibrosis showing hematologic responses, spleen volume reductions, symptom improvements and safety findings.
Beyond R&D, Incyte issues releases on leadership changes, board transitions, inducement equity grants and participation in major healthcare investor conferences. For investors and analysts, the INCY news page provides a centralized view of clinical, regulatory, corporate governance and capital markets developments affecting the company.
Incyte (NASDAQ:INCY) announced on December 2, 2025 a partnership with supermodel and entrepreneur Winnie Harlow to launch “The Power of Choice” campaign to raise awareness of vitiligo.
The campaign features two new videos where Harlow revisits her childhood, shares advice for others living with vitiligo, and encourages people to learn about the condition and discuss options with dermatologists. Incyte said the initiative aims to validate lived experiences and promote patient choice in managing vitiligo. The release directs readers to ThisIsVitiligo.com for more information and notes Winnie Harlow was compensated for participation.
Incyte (Nasdaq:INCY) appointed Richard Hoffman as Executive Vice President and General Counsel effective December 1, 2025. Mr. Hoffman will join the Executive Leadership Team and lead legal and compliance functions.
He brings more than 20 years of experience advising biopharma on corporate governance, strategic transactions, intellectual property and litigation, most recently as a partner in Goodwin's Life Sciences group. Mr. Hoffman has advised companies including Anthos Therapeutics, Compass Therapeutics, Deciphera, PepGen and Syntimmune, and previously held senior roles at Hybridon and Avitech. He holds a B.A. from Harvard, a J.D. from Columbia and an M.B.A. from Wharton.
Mr. Hoffman succeeds Sheila Denton, who will leave to pursue new opportunities and will provide transitional support into the new year.
Incyte (Nasdaq:INCY) will present at investor conferences in December 2025: Citi’s 2025 Global Healthcare Conference on Tuesday, December 2, 2025 at 11:15 AM ET and the 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025 at 1:20 PM ET. The presentations will be webcast live at Investor.Incyte.com and replays will be available for 30 days.
Incyte (NASDAQ:INCY) announced a positive CHMP opinion recommending approval of Minjuvi (tafasitamab) with lenalidomide and rituximab for adult patients with relapsed or refractory follicular lymphoma (FL) after ≥1 systemic therapy.
Phase 3 inMIND (n=548) showed median investigator-assessed PFS of 22.4 months vs 13.9 months (HR 0.43; P<0.0001); IRC-assessed median PFS was not reached vs 16.0 months (HR 0.41). Safety was described as manageable; common adverse reactions ≥20% included respiratory infections, diarrhea, rash, and fatigue. The CHMP opinion now goes to the European Commission for a final decision.
Incyte (Nasdaq:INCY) announced on November 6, 2025 the expansion of its Moments of Clarity program to include six new patient stories focused on nonsegmental vitiligo and pediatric mild-to-moderate atopic dermatitis (eczema). The release highlights individual journeys, the role of healthcare engagement, and patient experience with Opzelura (ruxolitinib) cream 1.5%. Opzelura's approved topical uses and age ranges are noted. The program directs audiences to MyMomentsOfClarity.com for multimedia stories; participants were compensated.
Incyte (Nasdaq: INCY) announced that more than 50 abstracts will be presented at the 2025 ASH Annual Meeting (Dec 6–9, 2025) in Orlando, highlighting clinical and translational data across MPNs, GVHD and other hematology programs.
Key highlights: oral presentations for the first‑in‑class mutCALR antibody INCA033989 (monotherapy and ruxolitinib combination) in myelofibrosis and essential thrombocythemia; axatilimab (Niktimvo) GVHD safety/interim data; multiple poster sessions across INCB programs, tafasitamab in follicular lymphoma, and real‑world ruxolitinib analyses.
Incyte will host an investor webcast on Dec 7, 2025, 11:00 a.m. – 12:30 p.m. ET to discuss the mutCALR oral presentation; replay available for 30 days.
Incyte (Nasdaq: INCY) will present at investor conferences in November 2025. Presentations are scheduled for Guggenheim Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 10:00 am ET and Jefferies Global Healthcare Conference (London) on Tuesday, November 18, 2025 at 11:00 am GMT. Both presentations will be webcast live at Investor.Incyte.com and will be available for replay for 30 days.
Incyte (Nasdaq:INCY) reported third-quarter 2025 results with $1.37 billion total revenues, up 20% YoY, and $1.15 billion net product revenues, up 19% YoY. Jakafi net product revenue was $791 million (+7% YoY) and Opzelura net product revenue was $188 million (+35% YoY). The company raised full‑year 2025 net product revenue guidance to $4.23–$4.32 billion and raised Jakafi guidance to $3.050–$3.075 billion while maintaining Opzelura guidance of $630–$670 million. GAAP diluted EPS was $2.11 for the quarter and cash plus marketable securities totaled $2.9 billion as of September 30, 2025.
Business updates include regulatory filings and anticipated data readouts for ruxolitinib XR, INCA033989, INCA33890, INCB161734 and multiple late‑stage studies; some programs were paused as part of pipeline prioritization.
Incyte (NASDAQ:INCY) and Enable Injections announced a strategic partnership on October 27, 2025 to develop and commercialize Incyte’s investigational mutCALR monoclonal antibody (INCA033989) using Enable’s enFuse® On-Body Delivery System.
Under the agreement Incyte obtains a worldwide, exclusive license to use enFuse with INCA033989 in essential thrombocythemia (ET) and myelofibrosis (MF), with potential expansion to other assets and indications. Financial terms include an upfront technology access fee, potential R&D and commercial milestones, and a transfer price for clinical and commercial supply of enFuse devices. enFuse is designed to deliver large-volume subcutaneous doses and enable flexible site-of-care, including at-home self-administration.
Incyte (NASDAQ:INCY) reported eight-week Phase 3b TRuE-AD4 results showing Opzelura (ruxolitinib cream) 1.5% significantly improved moderate atopic dermatitis in adults with inadequate response, intolerance or contraindication to topical corticosteroids and calcineurin inhibitors. At Week 8, 70.0% achieved EASI75 versus 18.5% vehicle and 61.3% achieved IGA-TS versus 13.6% vehicle (P<0.0001 each). Itch improved as early as Day 2 and 62.5% reached Itch NRS4 by Week 8. No serious infections, MACE, malignancies or thromboses were reported during the 8-week vehicle-controlled period. Incyte expects to file a Type-II variation for EU approval by year-end.
FAQ
What is the current stock price of Incyte (INCY)?
What is the market cap of Incyte (INCY)?
